TWO new clinical trials have confirmed that higher doses of semaglutide (Ozempic and Wegovy) can safely enhance weight loss and improve health for adults living with obesity.
With a currently approved dose of 2.4mg per week, the trials investigated whether a 7.2mg weekly dose of semaglutide can significantly improve weight loss and related health outcomes in adults living with obesity, including those with type 2 diabetes (T2D).
Trial participants were randomised to receive either a 7.2mg dose or a 2.4mg dose, or placebo, over 72 weeks.
All participants also received lifestyle interventions, such as dietary counselling and advice on physical activity.
In adults without diabetes, the 7.2mg dose led to an average weight loss of nearly 19%, compared with 16% with 2.4mg and 4% with placebo.
Similarly, in adults with obesity and T2D, the 7.2mg dose resulted in an average 13% weight loss compared with 10% with 2.4mg and 3.9% with placebo, along with significant reductions in blood sugar levels and waist size.
Both trials reported that the higher dose of semaglutide was safe and generally well tolerated, but noted longer studies were needed.
Read the research HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Sep 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Sep 25
